WC
FATE icon

Wexford Capital’s Fate Therapeutics FATE Stock Holding History

Wexford Capital’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-110,882
Closed -$2.25M – 127
2019
Q2 		$2.25M Hold
110,882
– – 0.26% 63
2019
Q1 		$1.95M Hold
110,882
– – 0.16% 54
2018
Q4 		$1.42M Buy
110,882
+79,082
+249% +$1.1M 0.12% 45
2018
Q3 		$518K Buy
+31,800
New +$376K 0.03% 119

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
GH
Grosvenor Holdings Chicago, Illinois $512M AUM 19.57% 1-Year Est. Return

Wexford Capital's FATE Position: Q3 2019 in Review

Wexford Capital sold out of Fate Therapeutics (FATE) in Q3 2019, closing a stake of 110,882 shares — an estimated $2.25M sold.

Wexford Capital first reported a position in FATE in Q3 2018 and held it in 4 quarters. The position peaked at $2.25M in Q2 2019. 149 funds tracked by Wall St. Rank hold FATE as of Q3 2019.

  • Wexford Capital reported no remaining Fate Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Wexford Capital sold 110,882 Fate Therapeutics shares in Q3 2019, an estimated $2.25M.
  • Wexford Capital first reported a position in Fate Therapeutics in Q3 2018 and held it in 4 quarters.
  • Wexford Capital's Fate Therapeutics position peaked at $2.25M in Q2 2019.
  • 149 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2019.

Based on Wexford Capital's 13F filing for Q3 2019, filed 14 Nov 2019.